药物载体用于递送肿瘤坏死因子相关凋亡诱导配体的研究进展  

Drug delivery systems of tumor necrosis factor-related apoptosis-inducing ligand in tumor therapy

作　　者：周安维 鞠曹云[1] 张灿[1] ZHOU Anwei;JU Caoyun;ZHANG Can(Center of Advanced Pharmaceuticals and Biomaterials,Center of New Drug Discovery,China Pharmaceutical University,Nanjing 210009,China)

机构地区：[1]中国药科大学新药研究中心高端药物制剂与材料研究中心,江苏南京210009

出　　处：《药学研究》2018年第9期523-527,共5页Journal of Pharmaceutical Research

基　　金：国家自然科学基金资助项目(No.81773664;81503003;81473153)

摘　　要：肿瘤坏死因子相关凋亡诱导配体(tumor necrosis factor-related apoptosis-inducing ligand,TRAIL)是肿瘤坏死因子家族的成员之一,可与肿瘤细胞膜表面过度表达的死亡受体4或5结合,特异性诱导肿瘤细胞凋亡,且对正常细胞无明显影响,因此被认为是临床最有发展前景的蛋白药物之一。然而,由于肿瘤坏死因子相关诱导凋亡配体存在体内稳定性差和生物利用度低等缺点,限制了其在临床中的应用。运用药物载体对肿瘤坏死因子相关诱导凋亡配体进行递送,成为目前解决此弊端的有效策略。本综述简要介绍了近年来药物载体在肿瘤坏死因子相关凋亡诱导配体递送方面的研究进展。Tumor necrosis factor-related apoptosis-inducing ligand （TRAIL） is a member of tumor necrosis factor family,which specifically binds to death receptor 4 or death receptor 5 overexpressed on the cell membrane surface of tumor cells,thus inducing cell apoptosis while sparing normal cells.Therefore,it has become one of the promising protein drug in tumor therapy.However,TRAIL exihits poor stability and bioavailability in vivo ,which strongly limits the clinical application.In order to potentiate beneficial properties of TRAIL,and avoid these disadvantages,drug carries were discovered,which emerging as a new strategy for TRAIL delivery.This review provided a brief overview of the recent advances in drug delivery of TRAIL.

关 键 词：肿瘤坏死因子相关凋亡诱导配体 药物递送载体 肿瘤治疗 

分 类 号：R945[医药卫生—微生物与生化药学]